Posted by
On January 24-25, 2022, the FDA and Duke-Margolis Center for Health Policy will host a virtual public
workshop on endpoint considerations to facilitate drug development for NPC. During this workshop,
participants will discuss clinical endpoints relevant to NPC clinical trials and innovative strategies to
support therapeutic development for patients with NPC. The workshop is open to the public and will
include representation from the patient community, the academic community, health care
providers, industry, and other federal partners.
Registration at the meeting website
Featured image: wikipedia